#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4038	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2163	506.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1446	1446	C	537	C,A	420,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6670	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4122	456.1	0	.	n	.	0	T695C	SNP	695	695	T	1323	1323	C	493	C	394	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6670	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4122	456.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1965	1965	A	539	A,C	428,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6670	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4122	456.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2599	2599	C	510	C	404	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6670	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4122	456.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2673	2673	A	533	A,C	423,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6670	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4122	456.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3225	3225	C	563	C	434	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	488	folP	855	855	100.0	folP.l15.c4.ctg.1	1956	70.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1176	1178	AGC	103;104;103	A;G;C,A	80;82;79,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	27	1262	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3790	93.4	1	SNP	p	S91F	1	.	.	271	273	TTC	713	715	TTC	83;83;83	T;T;C	70;69;71	gyrA.WHO_G_01105:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	27	1262	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3790	93.4	1	SNP	p	D95N	0	.	.	283	285	GAC	725	727	GAC	81;83;83	G;A;C	67;66;66	gyrA.WHO_G_01105:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	27	1262	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3790	93.4	1	SNP	p	D95G	0	.	.	283	285	GAC	725	727	GAC	81;83;83	G;A;C	67;66;66	gyrA.WHO_G_01105:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	546	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1673	92.1	1	SNP	p	G45D	1	.	.	133	135	GAC	634	636	GAC	137;137;137	G;A;C	100;100;107	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	360	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1364	74.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	27	1292	parC	2304	2304	99.78	parC.l6.c4.ctg.1	3610	100.7	1	SNP	p	D86N	0	.	.	256	258	GAC	1062	1064	GAC	121;119;119	G;A;C	93;93;95	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	27	1292	parC	2304	2304	99.78	parC.l6.c4.ctg.1	3610	100.7	1	SNP	p	S87W	0	.	.	259	261	AGT	1065	1067	AGT	119;118;118	A;G;T,C	91;97;98,1	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	27	1292	parC	2304	2304	99.78	parC.l6.c4.ctg.1	3610	100.7	1	SNP	p	S87I	0	.	.	259	261	AGT	1065	1067	AGT	119;118;118	A;G;T,C	91;97;98,1	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	27	1292	parC	2304	2304	99.78	parC.l6.c4.ctg.1	3610	100.7	1	SNP	p	S87R	0	.	.	259	261	AGT	1065	1067	AGT	119;118;118	A;G;T,C	91;97;98,1	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	27	1292	parC	2304	2304	99.78	parC.l6.c4.ctg.1	3610	100.7	1	SNP	p	S88P	0	.	.	262	264	TCC	1068	1070	TCC	119;119;117	T;C,A;C,G	96;95,1;95,1	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1078	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3082	98.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1787	1789	GGC	120;121;121	G;G;C	94;93;90	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1459	1461	GCA	128;130;132	G;C;A	95;92;96	penA.4.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1462	1464	ATC	132;131;131	A,C;T,A,G;C,A	94,1;92,2,1;92,3	penA.4.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1474	1476	GTG	144;146;148	G;T;G	105;99;106	penA.4.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1474	1476	GTG	144;146;148	G;T;G	105;99;106	penA.4.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1978	1980	ACC	103;103;102	A,C;C;C	80,2;86;87	penA.4.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2032	2034	GCG	94;93;94	G;C,T;G,T	73;64,1;71,1	penA.4.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2032	2034	GCG	94;93;94	G;C,T;G,T	73;64,1;71,1	penA.4.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2155	2157	AGC	103;103;102	A;G;C	82;82;85	penA.4.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2164	2166	GGC	101;101;100	G;G;C	82;82;79	penA.4.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	926	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2735	94.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2182	2184	CCG	105;107;106	C;C;G,A	85;90;82,1	penA.4.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1324	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3576	104.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1845	1847	CCG	113;116;117	C,G;C;G	85,1;87;83	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	696	porA	1146	1146	99.56	porA.l6.c4.ctg.1	2258	87.2	0	.	p	.	0	S22G	NONSYN	64	66	AGC	580	582	GGC	129;130;132	G;G;C	105;103;107	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	696	porA	1146	1146	99.56	porA.l6.c4.ctg.1	2258	87.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	762	762	C	112	C,T	83,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	516	86	porB1a	984	97	94.85	porB1a.l6.c4.ctg.1	1462	10.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	1417	1419	ACG	2;2;2	A;C;G	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	516	86	porB1a	984	97	94.85	porB1a.l6.c4.ctg.1	1462	10.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	1459	1461	CAA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	516	86	porB1a	984	100	95.0	porB1a.l6.c4.ctg.2	944	7.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	896	898	ACG	12;12;12	A;C;G	11;11;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	516	86	porB1a	984	100	95.0	porB1a.l6.c4.ctg.2	944	7.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	938	940	CAA	7;7;7	C;A;A	7;7;7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	562	564	GAA	154;155;154	G,A;A;A	116,1;119;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	D121G	NONSYN	361	363	GAC	811	813	GGC	154;154;153	G;G;C	126;123;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1009	1011	CAA	144;144;145	C;A,C;A	117;119,2;122	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1015	1017	AGC	147;146;145	A,G;G;C	115,1;119;121	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	Y211S	NONSYN	631	633	TAC	1081	1083	TCC	144;144;145	T;C,A;C	112;113,1;116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	N213D	NONSYN	637	639	AAT	1087	1089	GAT	145;145;145	G,T;A;T	113,2;114;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	F215T	NONSYN	643	645	TTT	1093	1095	ACT	144;143;141	A;C;T	114;113;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1102	1104	GTG	142;142;142	G,T;T;G	110,1;113;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	F222L	NONSYN	664	666	TTT	1114	1116	TTG	144;145;145	T,G;T,G;G	117,1;119,1;116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	0	.	p	.	0	A242V	NONSYN	724	726	GCC	1174	1176	GTT	139;140;140	G,T;T;T	114,1;119;116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	1950	109.1	1	SNP	p	G120K	1	.	.	358	360	AAG	808	810	AAG	154;154;154	A;A;G	123;124;125	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2566	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5427	133.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	424	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1442	83.4	1	SNP	p	V57M	1	.	.	169	171	ATG	648	650	ATG	175;175;178	A,C;T;G	140,1;141;138	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
